Nivolumab with chemotherapy for newly diagnosed PMBL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a fixed low dose of nivolumab combined with standard chemo-immunotherapy for people newly diagnosed with primary mediastinal B-cell lymphoma. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of primary mediastinal B-cell lymphoma (a type of lymphoma in the chest area).
- Your heart function (ejection fraction) must be greater than 50%.
- You must be able to perform daily activities with minimal help (ECOG score 0-2).
- You cannot have active infections, severe organ problems, or a history of autoimmune disease.
- You must not be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding nivolumab (an immunotherapy drug) to a standard chemotherapy regimen for children with primary mediastinal large B-cell lymphoma. It may help improve outcomes for newly diagnosed patients.
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
This study looks at how well two immunotherapy medicines—pembrolizumab alone or nivolumab combined with brentuximab vedotin—work for people with a type of lymphoma in the chest that has come back or not responded to treatment. It uses real-world data from patients who received these treatments outside of a clinical trial.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
Hear when a new Primary Mediastinal Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.